About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Products
Overview
Product Locator
Business
Overview
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Global Footprint
Partners
Branded Formulations India
Metabolics
Oncology
Immunotherapy
Nephrology
CCD
COVID-19 Care Portfolio
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Biocon Biologics Malaysia
Commitment
Overview
Investors
Overview
Governance & Policies
News
Overview
Press Releases
Company Statements
Stories
Media Contacts
Careers
Working With Us
Now Hiring
Stories
Contact Us
Brand Stories
Employee Stories
Patient Stories
Uncategorized
Biocon Biologics
/
News – Posts
/
Uncategorized
Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada
Thu, 19-May-2022
Posted by: Biocon Biologics
No Comments
